This page shows the latest Evotec news and features for those working in and with pharma, biotech and healthcare.
It’s also been working with Evotec on therapies for neurodegenerative disorders using the German biotech’s stem cell screening platform, and has accelerated its R&D efforts in CNS after
Evotec has been building capabilities in infectious disease research since acquiring Euprotek (UK) in 2014. ... the progress of novel anti-infectives on Evotec’s platform will be a key success factor”.
Partners with Kyoto University on R&D-focused work
Evotec invests 15m in AI firm Exscientia. Funds will help the Scottish group accelerate growth. ... As per the investment, Evotec’s chief operating officer, Dr Mario Polywka, will join Exscientia’s board of directors. .
Evotec acquires Aptuit for $300m. The move expands the group’s leadership in external innovation. ... The acquisition will see Evotec drive its efforts on investigational new drug submissions, integrated drug substance, drug products and commercial
Exscientia, which says it's the first company to "automate drug design", is already working with the likes of Evotec in immuno-oncology and Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals in
More from news
Approximately 10 fully matching, plus 23 partially matching documents found.
For example, Evotec, the German small molecule development company, is acquiring for $300m the US preclinical development company, Aptuit. ... 400. Aptuit (US). Evotec (DE). Company acquisition. Drug discovery and development to IND submission including
320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for neurodegenerative diseases. ... upfront. And although the upfronts are a modest percentage of the headline figure, ranging from < 1% (BioInvent) to 15%
Acquisition of Priority Review Voucher. 350. Evotec. Sanofi. Beta cell modulating treatments for diabetes. ... Acquisition ‐ company. 300. Aperion Biologics Evotec. Sanofi. To develops mall molecule immuno‐ therapies.
Company acquisition. 375. Evotec / Sanofi. R&D alliance to progress Sanofi discovery phase compounds to preclinical stage (inc Sanofi discovery facility with 200 scientists).
130. Evotec /Janssen. R&D collaboration. Target AD collaboration to identify novel therapies for Alzheimer's.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
He has also served on several boards including Ablynx, Evotec and Acambis.
Evotec CEO Werner Lanthaler temporarily stands down. Cites health reasons. Evotec's CEO Dr Werner Lanthaler, has temporarily stood down from his role within the company due to health reasons.
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...